Bangladeshi glaucoma eye drop manufacturer banned from supplying products in Europe
Bangladesh-based Beximco Pharmaceuticals has been prohibited from supplying its timolol and latanoprost prescription eye drops for glaucoma in the EU and EEA markets on the back of facility design concerns.
The facility’s GMP certificate, originally issued in January 2020, will be withdrawn. The Malta Medicines Authority found one critical, three major and 15 other deficiencies after it conducted an inspection between July 28 and Aug. 1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.